These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 11517956)

  • 1. Effect of long-term recombinant growth hormone therapy in children--the National Cooperative Growth Study, USA, 1985-1994.
    Root AW; Kemp SF; Rundle AC; Dana K; Attie KM
    J Pediatr Endocrinol Metab; 1998; 11(3):403-12. PubMed ID: 11517956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center.
    Al Shaikh A; Daftardar H; Alghamdi AA; Jamjoom M; Awidah S; Ahmed ME; Soliman AT
    Acta Biomed; 2020 Mar; 91(1):29-40. PubMed ID: 32191651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight relative to height before and during growth hormone therapy in prepubertal children.
    Kaplowitz PB; Rundle AC; Blethen SL
    Horm Metab Res; 1998 Sep; 30(9):565-9. PubMed ID: 9808325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment.
    Soliman A; Rogol AD; Elsiddig S; Khalil A; Alaaraj N; Alyafie F; Ahmed H; Elawwa A
    J Pediatr Endocrinol Metab; 2021 Oct; 34(10):1263-1271. PubMed ID: 34291621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses to growth hormone (GH) therapy in short children with normal GH secretion and no bone age delay: an analysis of potential factors affecting their response to rhGH therapy. A controlled study.
    Soliman AT; Elawwa A; Itani M; Jour C; De Sanctis V
    Acta Biomed; 2019 Sep; 90(8-S):43-51. PubMed ID: 31544806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Near adult heights after growth hormone treatment in patients with idiopathic short stature or idiopathic growth hormone deficiency.
    Frindik JP; Kemp SF; Hunold JJ
    J Pediatr Endocrinol Metab; 2003 May; 16 Suppl 3():607-12. PubMed ID: 12795361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of spontaneous or induced puberty on the growth promoting effect of treatment with growth hormone in girls with Turner's syndrome.
    Massa G; Maes M; Heinrichs C; Vandeweghe M; Craen M; Vanderschueren-Lodeweyckx M
    Clin Endocrinol (Oxf); 1993 Mar; 38(3):253-60. PubMed ID: 8458097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children.
    Hou L; Liang Y; Wu W; Lin HH; Luo XP; Ying YQ
    Growth Horm IGF Res; 2020; 53-54():101331. PubMed ID: 32777706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Dutch Growth Hormone Working Group.
    Wit JM; Boersma B; de Muinck Keizer-Schrama SM; Nienhuis HE; Oostdijk W; Otten BJ; Delemarre-Van de Waal HA; Reeser M; Waelkens JJ; Rikken B
    Clin Endocrinol (Oxf); 1995 Apr; 42(4):365-72. PubMed ID: 7750190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort.
    Maghnie M; Ranke MB; Geffner ME; Vlachopapadopoulou E; Ibáñez L; Carlsson M; Cutfield W; Rooman R; Gomez R; Wajnrajch MP; Linglart A; Stawerska R; Clayton PE; Darendeliler F; Hokken-Koelega ACS; Horikawa R; Tanaka T; Dörr HG; Albertsson-Wikland K; Polak M; Grimberg A
    J Clin Endocrinol Metab; 2022 Nov; 107(12):3287-3301. PubMed ID: 36102184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy.
    Ballerini MG; Braslavsky D; Scaglia PA; Keselman A; Rodríguez ME; Martínez A; Freire AV; Domené HM; Jasper HG; Bergadá I; Ropelato MG
    Horm Res Paediatr; 2017; 88(5):354-363. PubMed ID: 28926833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Overall Safety of NutropinAq
    Coutant R; Bosch Muñoz J; Dumitrescu CP; Schnabel D; Sert C; Perrot V; Dattani M
    Front Endocrinol (Lausanne); 2021; 12():676083. PubMed ID: 34113318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of different definitions of growth response in short prepubertal children treated with growth hormone.
    Bang P; Bjerknes R; Dahlgren J; Dunkel L; Gustafsson J; Juul A; Kriström B; Tapanainen P; Aberg V
    Horm Res Paediatr; 2011; 75(5):335-45. PubMed ID: 21228552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the Kabi International Growth Study, April 1989.
    Acta Paediatr Scand Suppl; 1989; 356():173-7. PubMed ID: 2816356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency.
    Zavras N; Meazza C; Pilotta A; Gertosio C; Pagani S; Tinelli C; Bozzola M
    Ital J Pediatr; 2015 Oct; 41():71. PubMed ID: 26444854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety of recombinant human growth hormone in turner syndrome.
    Bolar K; Hoffman AR; Maneatis T; Lippe B
    J Clin Endocrinol Metab; 2008 Feb; 93(2):344-51. PubMed ID: 18000090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation.
    Takeda A; Cooper K; Bird A; Baxter L; Frampton GK; Gospodarevskaya E; Welch K; Bryant J
    Health Technol Assess; 2010 Sep; 14(42):1-209, iii-iv. PubMed ID: 20849734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attaining genetic height potential: Analysis of height outcomes from the ANSWER Program in children treated with growth hormone over 5 years.
    Ross JL; Lee PA; Gut R; Germak J
    Growth Horm IGF Res; 2015 Dec; 25(6):286-93. PubMed ID: 26363846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database).
    Darendeliler F; Ranke MB; Bakker B; Lindberg A; Cowell CT; Albertsson-Wikland K; Reiter EO; Price DA
    Horm Res; 2005; 63(1):40-7. PubMed ID: 15627781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Height Gain and Safety Outcomes in Growth Hormone-Treated Children with Idiopathic Short Stature: Experience from a Prospective Observational Study.
    Child CJ; Quigley CA; Cutler GB; Moore WV; Wintergerst KA; Ross JL; Rosenfeld RG; Blum WF
    Horm Res Paediatr; 2019; 91(4):241-251. PubMed ID: 31185471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.